Novel CCR5 antagonists for the treatment of HIV infection: a review of compounds patented in 2006 - 2008. (Q37697793)

22 August 2017

1 reference

title

Novel CCR5 antagonists for the treatment of HIV infection: a review of compounds patented in 2006 - 2008. (English)

1 reference

22 August 2017

0 references

Hanbiao Yang

1

1 reference

22 August 2017

David M Rotstein

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Therapeutic Patents

22 August 2017

published in

1 reference

22 August 2017

volume

20

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

325-354

1 reference

Inhibitors of viral entry

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

The HIV entry inhibitors revisited.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

Prospects of HIV-1 entry inhibitors as novel therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

The chemokine receptor, CCR5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

Identification of a major co-receptor for primary isolates of HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

CCR5 inhibitors in HIV-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: modifications of the arylpropylpiperidine side chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

1,3,4 Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

Maraviroc: a new CCR5 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

Spiropiperidine CCR5 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

Synthesis and biological evaluation of 1,3,3,4-tetrasubstituted pyrrolidine CCR5 receptor antagonists. Discovery of a potent and orally bioavailable anti-HIV agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

Understanding the Structure−Activity Relationship of the Human Ether-a-go-go-Related Gene Cardiac K+ Channel. A Model for Bad Behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

CCR5 antagonists: the answer to inflammatory disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903575674

10.1517/13543770903575674

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference